STOCK TITAN

Artelo Biosciences, Inc. - ARTL STOCK NEWS

Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.

Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.

Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.

One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.

Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.

Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.

Rhea-AI Summary
Artelo Biosciences, Inc. (ARTL) will participate in the Winter Wrap-Up MicroCap Rodeo Conference to present their lipid-signaling pathways treatments for cancer, pain, and neurological conditions. CEO Gregory D. Gorgas will present on February 20th and meet with investors on February 22nd and 23rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
conferences
-
Rhea-AI Summary
Artelo Biosciences, Inc. (ARTL) announced new research published in the peer-reviewed Journal of Pain, highlighting its pre-clinical asset, ART26.12, and its potential ability to treat and prevent Oxaliplatin-Induced Peripheral Neuropathy. The global neuropathic pain market is estimated at $7.6 billion, demonstrating the need for innovative therapy. Artelo has conducted multiple pre-clinical studies in painful neuropathies and anticipates filing the IND for ART26.12 in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary
Artelo Biosciences, a clinical-stage pharmaceutical company (Nasdaq: ARTL), has selected Worldwide Clinical Trials to support its Phase 1 trial with ART26.12, a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy. The global neuropathic pain market is valued at $7.6 billion, showing the need for innovative therapies. Artelo anticipates filing the IND for ART26.12 in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), demonstrating improved CBD bioavailability and efficacy in both the fed and fasted states compared to CBD alone. The presentation at the 4th Annual Med-Cannabis 2023 conference discussed greater anxiolytic, anti-depressive, and pro-social effects of ART12.11 compared to CBD alone, highlighting its potential therapeutic utility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
-
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that George Warren, PhD., will present new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol (CBD) and tetremethylpyrazine (TMP), at the 4th Annual Med-Cannabis 2023 conference in Frankfurt, Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences clinical trial
-
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) Reports $12.9 Million in Cash and Investments as of September 30, 2023; On Track to Submit IND Application with the FDA for ART26.12 in 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Artelo Biosciences, Inc. (Nasdaq: ARTL) announced groundbreaking research in the Pharmaceuticals journal highlighting the protective properties of ART27.13 in preventing muscle degeneration caused by cancer. The research supports the potential of ART27.13 as a supportive care therapy for cancer patients, with ongoing evaluation in the Cancer Appetite Recovery Study Phase 2a clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Artelo Biosciences, a clinical-stage pharmaceutical company, will be presenting two programs at Neuroscience 2023. One program focuses on ART26.12, an inhibitor that modulates signaling pathways related to depressive and anxiety-related behaviors. The other program showcases ART12.11, a cocrystal of cannabidiol and tetramethylpyrazine that has shown improved efficacy in a model of anxiety and depression. Artelo plans to file an IND application in the first half of 2024 for ART26.12 to treat neuropathic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences clinical trial
-
Rhea-AI Summary
Artelo Biosciences announces virtual medical expert webinar on cancer-related anorexia and cachexia treatment landscape, featuring lead candidate ART27.13 in Phase 2a clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
Rhea-AI Summary
Artelo Biosciences to present at EFIC Congress on the effects of FABP5 Inhibitor in peripheral neuropathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
conferences

FAQ

What is the current stock price of Artelo Biosciences (ARTL)?

The current stock price of Artelo Biosciences (ARTL) is $0.9476 as of December 20, 2024.

What is the market cap of Artelo Biosciences (ARTL)?

The market cap of Artelo Biosciences (ARTL) is approximately 3.0M.

What does Artelo Biosciences do?

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system.

Where is Artelo Biosciences headquartered?

Artelo Biosciences is headquartered in San Diego, California, with an additional office in Dublin, Ireland.

What are the main therapeutic areas Artelo Biosciences focuses on?

Artelo Biosciences focuses on developing treatments for anorexia, cancer, anxiety, pain, neuropathy, and inflammation.

What is ART12.11?

ART12.11 is Artelo’s proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP), which has shown improved bioavailability and efficacy compared to standard CBD compositions.

What is ART26.12?

ART26.12 is a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed by Artelo as a non-opioid, non-steroidal analgesic for treating chemotherapy-induced peripheral neuropathy (CIPN) and other neuropathic pains.

What is ART27.13?

ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors, currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial to improve body weight, appetite, and muscle degeneration in cancer patients.

What recent achievement has ART12.11 demonstrated?

ART12.11 has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone, providing better pharmacokinetics and efficacy.

What progress has been made in the ART26.12 program?

In preclinical studies, ART26.12 has shown efficacy in reducing pain in models of chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy.

Who leads Artelo Biosciences?

Artelo Biosciences is led by experienced biopharmaceutical executives working in collaboration with highly respected researchers and technology experts.

Where can I find more information about Artelo Biosciences?

More information about Artelo Biosciences is available on their website, www.artelobio.com, and on Twitter @ArteloBio.

Artelo Biosciences, Inc.

Nasdaq:ARTL

ARTL Rankings

ARTL Stock Data

3.00M
3.20M
0.83%
0.72%
0.62%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH